TY  - JOUR 
AU  - Palomeras, S.
AU  - Díaz Lagares, Ángel
AU  - Viñas, G.
AU  - Setien, F.
AU  - Ferreira, H. J.
AU  - Oliveras, G.
AU  - Crujeiras Martínez, Ana Belén
AU  - Hernández, A.
AU  - Lum, D. H.
AU  - Welm, A. L.
AU  - Esteller, M.
AU  - Puig, T.
PY  - 2019
SN  - 1465-5411
UR  - http://hdl.handle.net/20.500.11940/15527
AB  - BACKGROUND: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this...
TI  - Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
DO  - 10.1186/s13058-019-1160-x
T2  - BREAST CANCER RESEARCH
M2  - 79
KW  - IDIS
VL  - 21
ER  -